GGS
ABBV icon

Galvin Gaustad & Stein’s AbbVie ABBV Stock Holding History

Galvin Gaustad & Stein’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Buy
6,895
+1,031
+18% +$222K 0.13% 103
2026
Q1 		$1.28M Buy
5,864
+297
+5% +$65.9K 0.1% 115
2025
Q4 		$1.27M Buy
5,567
+61
+1% +$13.9K 0.1% 108
2025
Q3 		$1.27M Buy
5,506
+629
+13% +$128K 0.1% 94
2025
Q2 		$905K Sell
4,877
-1
-0% -$186 0.08% 105
2025
Q1 		$1.02M Buy
4,878
+673
+16% +$131K 0.09% 97
2024
Q4 		$747K Sell
4,205
-28
-0.7% -$5.15K 0.07% 110
2024
Q3 		$836K Buy
4,233
+763
+22% +$142K 0.07% 103
2024
Q2 		$595K Buy
3,470
+16
+0.5% +$2.65K 0.06% 118
2024
Q1 		$629K Sell
3,454
-69
-2% -$11.9K 0.06% 108
2023
Q4 		$546K Sell
3,523
-419
-11% -$61.1K 0.05% 115
2023
Q3 		$588K Sell
3,942
-96,897
-96% -$14.2M 0.06% 107
2023
Q2 		$13.6M Sell
100,839
-9,619
-9% -$1.41M 1.32% 34
2023
Q1 		$17.6M Sell
110,458
-1,842
-2% -$282K 1.73% 24
2022
Q4 		$18.1M Buy
112,300
+6,352
+6% +$974K 1.83% 21
2022
Q3 		$14.2M Sell
105,948
-5,796
-5% -$832K 1.51% 29
2022
Q2 		$17.1M Sell
111,744
-17,273
-13% -$2.64M 1.74% 23
2022
Q1 		$20.9M Sell
129,017
-24,162
-16% -$3.51M 1.89% 16
2021
Q4 		$20.7M Sell
153,179
-10,115
-6% -$1.19M 1.79% 18
2021
Q3 		$17.6M Buy
+163,294
New +$18.7M 1.7% 19

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Galvin Gaustad & Stein's ABBV Position: Q2 2026 in Review

Galvin Gaustad & Stein increased its AbbVie (ABBV) stake by 18% in Q2 2026, buying an estimated $222K and bringing the position to 6,895 shares worth $1.74M. The position accounts for 0.13% of the portfolio, ranked #103.

Galvin Gaustad & Stein first reported a position in ABBV in Q3 2021 and has held it in 20 quarters since. The position peaked at $20.9M in Q1 2022. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Galvin Gaustad & Stein held 6,895 shares of AbbVie worth $1.74M as of Q2 2026.
  • Galvin Gaustad & Stein bought 1,031 AbbVie shares in Q2 2026, an estimated $222K.
  • AbbVie made up 0.13% of Galvin Gaustad & Stein's portfolio in Q2 2026, its #103 holding.
  • Galvin Gaustad & Stein first reported a position in AbbVie in Q3 2021 and has held it in 20 quarters since.
  • Galvin Gaustad & Stein's AbbVie position peaked at $20.9M in Q1 2022.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Galvin Gaustad & Stein's 13F filing for Q2 2026, filed 29 Jul 2026.